REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing
18 August 2021
Yokohama Japan, 18 August 2021: REPROCELL have signed a Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufa...
REPROCELL highlights the power of human fresh tissue in global publication
05 July 2021
Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled "Human Fresh Tissue VS Clinical Attrition", explains th...
REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite
29 June 2021
Maryland, USA: REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs). At this new US facility, REPROCELL will provide a comprehensive workflow of clinical st...
REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant
21 June 2021
Yokohama, Japan: We are pleased to announce that REPROCELL will launch a new testing service of identification for Covid-19 variants, including the Indian (Delta), UK, South African, and Brazilian variants. These have all been identified as...
Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan
24 May 2021
We are pleased to announce that administrations of Stemchymal, a regenerative medicine product derived from somatic stem cells, have been completed to all enrolled patients in phase II clinical trial for the treatment of spinocerebellar ata...
VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL
18 May 2021
Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical researc...
REPROCELL will participate at the Biotechgate Digital Partnering Event.
21 April 2021
REPROCELL USA and REPROCELL Europe will be attending all 5 days of the Biotechgate Digital Partnering 2021 Event, 3-7 May 2021. Partnering scheduling is now open, and registration is free. Have a one-on-one Zoom meeting with our experts and...
19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.
19 April 2021
Hyderabad India – 19 April 2021: Bioserve Biotechnologies India Pvt Ltd, a 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of clinical oncology diagnostic service in India. This new service is clinician-friendly, a...
Launch of New Testing Service of Identification for Covid-19 Variants
08 April 2021
We are pleased to announce that on Tuesday 6th April 2021, REPROCELL launched a new testing service for the identification for Covid-19 variants using the Allplex SARS-CoV-2 Variants I Assay (referred to below as Allplex) manufactured by Se...
REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan
22 March 2021
YOKOHAMA, 22 March, 2021/ REPROCELL has initiated a collaboration with Blacktrace Holdings Ltd in the sales of their Nadia series: a single-cell analytical system, in Japan. Single-cell analysis, or analysis of cell characteristics at the s...